Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Eledon Pharmaceuticals, Inc.

< Previous 1 2 Next >
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN URGN
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Provides Business and Pipeline Updates
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.